aripiprazole vs brexpiprazole
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aripiprazole and brexpiprazole. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Abilify
Rexulti
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems. It can help to improve your mood, thinking, and behavior.
Rexulti is a medication used to treat certain mental health conditions. It can help with depression, schizophrenia, and agitation related to Alzheimer's disease.
Aripiprazole is used to treat schizophrenia in adults and teens. It also treats irritability in children with autism. Additionally, it can treat Tourette's disorder.
Rexulti can be used with antidepressants to treat major depressive disorder in adults. It can also treat schizophrenia in adults and children 13 years and older. Additionally, Rexulti can help manage agitation in people with dementia due to Alzheimer's disease. Rexulti should not be used as needed for agitation related to dementia.
Aripiprazole works by affecting the levels of certain chemicals in the brain. These chemicals, like dopamine and serotonin, can affect mood and behavior. By balancing these chemicals, aripiprazole helps to reduce symptoms of mental health conditions.
Rexulti affects the balance of certain natural chemicals in the brain. These chemicals, called neurotransmitters, include dopamine and serotonin. By affecting these chemicals, Rexulti can help improve mood, thinking, and behavior.
- • Nausea
- • Vomiting
- • Constipation
- • Headache
- • Dizziness
- • Weight gain
- • Feeling sleepy
- • Restlessness or feeling like you need to move
- Weight Increased 7,698
- Anxiety 4,993
- Fatigue 4,188
- Suicidal Ideation 3,991
- Depression 3,950
- Weight Increased 1,673
- Akathisia 854
- Tremor 630
- Anxiety 591
- Tardive Dyskinesia 590
Aripiprazole may increase the risk of death in elderly patients who have psychosis related to dementia. It is not approved for this use. Antidepressants may increase the risk of suicidal thoughts and behaviors in children, teens, and young adults. Watch closely for worsening mood or suicidal thoughts.
Elderly patients with dementia-related psychosis who are treated with antipsychotic drugs have an increased risk of death. Rexulti is not approved to treat dementia-related psychosis unless it is related to agitation from Alzheimer's disease. Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults and children. Tell your doctor right away if you have thoughts of harming yourself.
If you are pregnant or plan to become pregnant, talk to your doctor. Aripiprazole may cause withdrawal symptoms or other problems in newborns if taken during the third trimester. There is a pregnancy registry for women who take aripiprazole during pregnancy.
Tell your doctor if you are pregnant or plan to become pregnant. Babies born to mothers who take Rexulti in the last 3 months of pregnancy may have withdrawal symptoms or other problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to Rexulti during pregnancy. You can contact the registry at 1-866-961-2388.
Also Compare, Nearby Drugs
Compare aripiprazole with
Compare brexpiprazole with
How to Read This aripiprazole vs brexpiprazole Comparison
aripiprazole is classified in the Atypical Antipsychotic drug class, while brexpiprazole sits within the Atypical Antipsychotic class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aripiprazole has 24,820 submissions while brexpiprazole has 4,338. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aripiprazole or brexpiprazole.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.